New Delhi: Pharmaceutical major Lupin said that the US health regulator USFDA has completed inspection of its Aurangabad facility in Maharashtra without any observation.
The inspection was carried out by the United States Food and Drug Administration (USFDA) between February 10 to 14, 2020, Lupin said in a filing to the Bombay Stock Exchange (BSE).
The inspection concluded without any observation, it added.
“We are encouraged with the successful inspection at our Aurangabad facility. We continue to enhance our standards of quality and compliance across our manufacturing operations and remain committed to uphold the highest quality standards across all our sites,” Lupin MD Nilesh Gupta said.